Home LiteratureArticle Details
PMID: 15082921 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Review

Cyclins and breast cancer.

Journal of mammary gland biology and neoplasia ·Vol. 9 ·No. 1 ·2004-01-00 ·Pages 95-104

Sutherland RL, Musgrove EA

Abstract

The D-type and E-type cyclins control the G(1) to S phase transition during normal cell cycle progression and are critical components of steroid- and growth factor-induced mitogenesis in breast epithelial cells. Mammary epithelial cell-specific overexpression of these genes leads to mammary carcinoma, while in cyclin D1-deficient mice mammary gland development is arrested prior to lobuloalveolar development. Cyclin D1 null mice are resistant to mammary carcinoma induced by the neu and ras oncogenes, indicating an essential role for cyclin D1 in the development of some mammary cancers. Cyclin D1 and E1 are commonly overexpressed in primary breast cancer, with some evidence of an association with an adverse patient outcome. This observation may result in part from their ability to confer resistance to endocrine therapies. The functional consequences of cyclin E overexpression in breast cancer are likely related to its role in cell cycle progression, whereas that of cyclin D1 may also be a consequence of a more recently defined role in transcriptional regulation.

MeSH Terms
Animals Antineoplastic Agents, Hormonal/pharmacology Breast Neoplasms/genetics,physiopathology Carcinoma/genetics,physiopathology Cell Cycle/physiology Cell Proliferation Cell Transformation, Neoplastic Cyclin D1/biosynthesis,pharmacology Cyclin E/biosynthesis,pharmacology Disease Models, Animal Drug Resistance, Neoplasm Female Gene Expression Regulation, Neoplastic Humans Mammary Neoplasms, Animal/genetics,physiopathology Mice Oncogene Proteins/biosynthesis,pharmacology
Chemicals
Antineoplastic Agents, Hormonal CCNE1 protein, human Cyclin E Oncogene Proteins Cyclin D1
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Sutherland Robert L
Cancer Research Program, Garvan Institute of Medical Research, St Vincent's Hospital, Darlinghurst, Sydney, Australia. r.sutherland@garvan.org.au
Musgrove Elizabeth A
References (83)
83 references, click to expand
  1. C-myc gene expression alone is sufficient to confer resistance to antiestrogen in human breast cancer cells.
    Int J Cancer. 2002 May 1;99(1):35-42 PMID: 11948489
  2. Development of mice expressing a single D-type cyclin.
    Genes Dev. 2002 Dec 15;16(24):3277-89 PMID: 12502747
  3. The regulation of E2F by pRB-family proteins.
    Genes Dev. 1998 Aug 1;12(15):2245-62 PMID: 9694791
  4. Cyclin E, a potential prognostic marker for breast cancer.
    Cancer Res. 1994 Jan 15;54(2):380-5 PMID: 7903908
  5. Overexpression of C/EBPbeta-LIP, a naturally occurring, dominant-negative transcription factor, in human breast cancer.
    J Natl Cancer Inst. 1997 Dec 17;89(24):1887-91 PMID: 9414177
  6. Genetic evidence for the interactions of cyclin D1 and p27(Kip1) in mice.
    Mol Cell Biol. 2001 Feb;21(4):1319-28 PMID: 11158317
  7. Cyclin D1, EMS1 and 11q13 amplification in breast cancer.
    Breast Cancer Res Treat. 2003 Apr;78(3):323-35 PMID: 12755491
  8. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining.
    Cancer Res. 1994 Apr 1;54(7):1812-7 PMID: 8137296
  9. Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells.
    Cancer Res. 1983 Sep;43(9):3998-4006 PMID: 6871841
  10. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
    Clin Cancer Res. 1996 Jul;2(7):1177-84 PMID: 9816285
  11. A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer.
    Br J Cancer. 1996 Mar;73(6):728-34 PMID: 8611372
  12. Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells.
    Mol Endocrinol. 1996 May;10(5):488-98 PMID: 8732680
  13. Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells.
    Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):9042-6 PMID: 10908655
  14. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle.
    Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8022-6 PMID: 8058751
  15. Cyclin D1 overexpression induces progestin resistance in T-47D breast cancer cells despite p27(Kip1) association with cyclin E-Cdk2.
    J Biol Chem. 2001 Dec 14;276(50):47675-83 PMID: 11590147
  16. Cyclin D2 is a moderately oscillating nucleoprotein required for G1 phase progression in specific cell types.
    Oncogene. 1995 Jun 1;10(11):2125-34 PMID: 7784057
  17. Deletion of the p27Kip1 gene restores normal development in cyclin D1-deficient mice.
    Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):194-9 PMID: 11134518
  18. 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells.
    Oncogene. 1996 Jun 6;12(11):2315-24 PMID: 8649771
  19. Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells.
    Oncogene. 1998 Jun 4;16(22):2865-78 PMID: 9671407
  20. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment.
    Gene. 1995 Jun 14;159(1):11-8 PMID: 7607564
  21. Cyclin D1 and prognosis in human breast cancer.
    Int J Cancer. 1996 Apr 22;69(2):92-9 PMID: 8608989
  22. Frequent overexpression of the cyclin D1 oncogene in invasive lobular carcinoma of the breast.
    Cancer Res. 1998 Jul 1;58(13):2876-80 PMID: 9661905
  23. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice.
    Nature. 1994 Jun 23;369(6482):669-71 PMID: 8208295
  24. Cyclin D1 expression and patient outcome after tamoxifen therapy in estrogen receptor positive metastatic breast cancer.
    Oncol Rep. 2003 Jan-Feb;10(1):141-4 PMID: 12469160
  25. Cyclin E and survival in patients with breast cancer.
    N Engl J Med. 2002 Nov 14;347(20):1566-75 PMID: 12432043
  26. New functional activities for the p21 family of CDK inhibitors.
    Genes Dev. 1997 Apr 1;11(7):847-62 PMID: 9106657
  27. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions.
    Nat Med. 1995 Dec;1(12):1257-60 PMID: 7489405
  28. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer.
    Clin Cancer Res. 1999 Aug;5(8):2069-76 PMID: 10473088
  29. The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node.
    Oncogene. 2002 Jul 11;21(30):4680-90 PMID: 12096344
  30. Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3.
    Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4510-5 PMID: 11274368
  31. Cyclin D2 activates Cdk2 in preference to Cdk4 in human breast epithelial cells.
    Oncogene. 1997 Mar 20;14(11):1329-40 PMID: 9178893
  32. Redundant cyclin overexpression and gene amplification in breast cancer cells.
    Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):1112-6 PMID: 8430082
  33. Inhibition of the MAP kinase cascade blocks heregulin-induced cell cycle progression in T-47D human breast cancer cells.
    Oncogene. 1998 May 28;16(21):2803-13 PMID: 9652748
  34. The hallmarks of cancer.
    Cell. 2000 Jan 7;100(1):57-70 PMID: 10647931
  35. Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays.
    Br J Cancer. 2002 Feb 12;86(4):580-6 PMID: 11870541
  36. Initiating oncogenic event determines gene-expression patterns of human breast cancer models.
    Proc Natl Acad Sci U S A. 2002 May 14;99(10):6967-72 PMID: 12011455
  37. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer.
    J Natl Cancer Inst. 1998 Jun 3;90(11):814-23 PMID: 9625169
  38. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4.
    Mol Cell Biol. 1997 Sep;17(9):5338-47 PMID: 9271411
  39. Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution.
    Mol Cell Biol. 1997 Jul;17(7):4059-69 PMID: 9199341
  40. Linking cyclins to transcriptional control.
    Gene. 2002 Oct 16;299(1-2):35-55 PMID: 12459251
  41. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients.
    Nat Med. 1997 Feb;3(2):222-5 PMID: 9018243
  42. Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast.
    Clin Cancer Res. 1998 Apr;4(4):847-54 PMID: 9563877
  43. Cyclin D1 provides a link between development and oncogenesis in the retina and breast.
    Cell. 1995 Aug 25;82(4):621-30 PMID: 7664341
  44. Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells.
    Cancer Res. 2002 Dec 1;62(23):6916-23 PMID: 12460907
  45. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer.
    Cell. 2003 Aug 8;114(3):323-34 PMID: 12914697
  46. Regulation of cyclin D1 and p16(INK4A) is critical for growth arrest during mammary involution.
    Cancer Res. 2001 Dec 15;61(24):8811-9 PMID: 11751403
  47. A low abundance pool of nascent p21WAF1/Cip1 is targeted by estrogen to activate cyclin E*Cdk2.
    J Biol Chem. 2001 Nov 30;276(48):45433-42 PMID: 11581254
  48. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development.
    Genes Dev. 1995 Oct 1;9(19):2364-72 PMID: 7557388
  49. p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells.
    Cancer Res. 2003 Aug 1;63(15):4322-6 PMID: 12907598
  50. CDK inhibitors: positive and negative regulators of G1-phase progression.
    Genes Dev. 1999 Jun 15;13(12):1501-12 PMID: 10385618
  51. CDK-independent activation of estrogen receptor by cyclin D1.
    Cell. 1997 Feb 7;88(3):405-15 PMID: 9039267
  52. Alternative mammary oncogenic pathways are induced by D-type cyclins; MMTV-cyclin D3 transgenic mice develop squamous cell carcinoma.
    Oncogene. 2003 Jul 10;22(28):4425-33 PMID: 12853979
  53. Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients.
    Pathol Int. 2003 Feb;53(2):74-80 PMID: 12588434
  54. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene.
    Cell. 1988 Jul 1;54(1):105-15 PMID: 2898299
  55. Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer.
    Oncogene. 1999 Mar 18;18(11):1983-91 PMID: 10208420
  56. Differential modulation of cyclin gene expression by MYC.
    Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3685-9 PMID: 8386381
  57. Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation.
    Mol Endocrinol. 1995 Dec;9(12):1804-13 PMID: 8614416
  58. Expression and amplification of cyclin genes in human breast cancer.
    Oncogene. 1993 Aug;8(8):2127-33 PMID: 8336939
  59. To cycle or not to cycle: a critical decision in cancer.
    Nat Rev Cancer. 2001 Dec;1(3):222-31 PMID: 11902577
  60. Cyclin D1 in breast cancer.
    Breast Cancer Res Treat. 1998;52(1-3):1-15 PMID: 10066068
  61. Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint.
    Mol Cell Biol. 1996 Dec;16(12):6917-25 PMID: 8943347
  62. A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence.
    J Biol Chem. 2000 Dec 8;275(49):38221-9 PMID: 10991938
  63. Cooperation of p27(Kip1) and p18(INK4c) in progestin-mediated cell cycle arrest in T-47D breast cancer cells.
    Mol Cell Biol. 2000 Apr;20(7):2581-91 PMID: 10713180
  64. Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer.
    Oncogene. 2003 Jul 31;22(31):4898-904 PMID: 12894232
  65. Mechanisms of cyclin-dependent kinase inactivation by progestins.
    Mol Cell Biol. 1998 Apr;18(4):1812-25 PMID: 9528753
  66. Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens.
    Cancer Res. 2002 Jun 1;62(11):3126-31 PMID: 12036924
  67. Rescue of cyclin D1 deficiency by knockin cyclin E.
    Cell. 1999 Jun 11;97(6):767-77 PMID: 10380928
  68. Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression.
    Mol Cell Biol. 1993 Jun;13(6):3577-87 PMID: 8497271
  69. Specific protection against breast cancers by cyclin D1 ablation.
    Nature. 2001 Jun 28;411(6841):1017-21 PMID: 11429595
  70. Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E.
    Mol Cell Biol. 1997 Jan;17(1):453-9 PMID: 8972226
  71. Cyclin E as a coactivator of the androgen receptor.
    J Cell Biol. 2000 Aug 21;150(4):873-80 PMID: 10953010
  72. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2.
    J Biol Chem. 1997 Apr 18;272(16):10882-94 PMID: 9099745
  73. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation.
    Cancer Res. 2001 Mar 15;61(6):2782-7 PMID: 11289162
  74. Regulation of the functional interaction between cyclin D1 and the estrogen receptor.
    Mol Cell Biol. 2000 Dec;20(23):8667-75 PMID: 11073968
  75. c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry.
    Mol Cell Biol. 1998 Aug;18(8):4499-508 PMID: 9671459
  76. Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer.
    Clin Cancer Res. 1996 Jun;2(6):923-8 PMID: 9816251
  77. Determination of the prognostic value of cyclin D1 overexpression in breast cancer.
    Oncogene. 1995 Sep 7;11(5):885-91 PMID: 7675447
  78. Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes.
    Cell. 1984 Oct;38(3):627-37 PMID: 6488314
  79. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo.
    Cell. 1987 May 22;49(4):465-75 PMID: 3032456
  80. The oncogenic activity of cyclin E is not confined to Cdk2 activation alone but relies on several other, distinct functions of the protein.
    J Biol Chem. 2002 Oct 18;277(42):39909-18 PMID: 12149264
  81. Principles of CDK regulation.
    Nature. 1995 Mar 9;374(6518):131-4 PMID: 7877684
  82. Constitutive MEK/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells.
    J Biol Chem. 2001 Nov 2;276(44):40888-95 PMID: 11527971
  83. Functional analysis of cyclin D2 and p27(Kip1) in cyclin D2 transgenic mouse mammary gland during development.
    Oncogene. 2002 Oct 17;21(47):7214-25 PMID: 12370811
Article Info
Journal
Journal of mammary gland biology and neoplasia
Abbr.
J Mammary Gland Biol Neoplasia
ISSN
1083-3021
DOI
10.1023/B:JOMG.0000023591.45568.77
Email
r.sutherland@garvan.org.au
Published
2004-01-00
Pages
95-104
Language
English
Region
United States
NLM ID
9601804
Subset
IM
External Links
PubMed source DOI: 10.1023/B:JOMG.0000023591.45568.77 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2